CANF Company Profile and Key Details

Q: Who are the executives of CANF?

Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D.Senior Clinical AdvisorDr. Sari Fishman Ph.D.Vice President of Bus. Devel.Dr. Pnina Fishman Ph.D.Founder, Chief Scientific Officer & Executive ChairmanDr. Vibeke S. Strand FACP, FACR, FACR (USA), M.D.Senior Clinical AdvisorMr. Motti FarbsteinChief Executive Officer & Chief Operating and Financial OfficerDr. Ilan Cohn Ph.D.Co-Founder & Director

AMEX : CANF

Can-Fite BioPharma

$0.25

0.0021+0.84%

At Close 4:00 PM

66.28

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Can-Fite BioPharma Ltd. (CANF) stock declined over -2.94%, trading at $0.24 on AMEX, down from the previous close of $0.25. The stock opened at $0.26, fluctuating between $0.24 and $0.26 in the recent session.

Stock Snapshot

0.2521

Prev. Close

2.63M

Market Cap

0.2417

Day Low

-0.09

P/E Ratio

-2.6

EPS (TTM)

0.02

Cash Flow per Share

0.26

Open

10.76M

Number of Shares

0.2582

Day High

27,304.3%

Free Float in %

1.38

Book Value

977.59K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 19, 2025	0.25	0.26	0.25	0.25	729.71K
Dec 17, 2025	0.28	0.29	0.27	0.27	615.49K
Dec 16, 2025	0.28	0.30	0.27	0.29	1.63M
Dec 15, 2025	0.29	0.29	0.26	0.27	629.35K
Dec 12, 2025	0.29	0.30	0.28	0.28	620.82K
Dec 11, 2025	0.30	0.31	0.29	0.29	787.79K
Dec 10, 2025	0.31	0.32	0.30	0.31	465.7K
Dec 09, 2025	0.33	0.33	0.31	0.32	797.57K
Dec 08, 2025	0.33	0.33	0.32	0.33	462.28K
Dec 05, 2025	0.34	0.34	0.31	0.31	884.11K
Dec 04, 2025	0.33	0.35	0.33	0.34	1.06M
Dec 03, 2025	0.36	0.37	0.34	0.34	706.67K
Dec 02, 2025	0.39	0.39	0.34	0.37	1.2M
Dec 01, 2025	0.35	0.39	0.35	0.39	2.62M
Nov 28, 2025	0.34	0.36	0.34	0.35	849.85K
Nov 26, 2025	0.34	0.36	0.32	0.34	1.61M
Nov 25, 2025	0.32	0.34	0.30	0.34	1.3M
Nov 24, 2025	0.30	0.36	0.29	0.33	3.25M
Nov 21, 2025	0.31	0.31	0.28	0.29	2.46M
Nov 20, 2025	0.33	0.35	0.30	0.31	4.89M

Contact Details

Petah Tikva, 4951778

Israel

https://www.canfite.com 972 392 41114

About Company

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Stock Peers

TBXU

1.0914+3.58%

Direxion Shares ETF Trust$31.54 PTN

-2.04-10.69%

Palatin Technologies, Inc.$17.05 AGE

-1.5-11.90%

AgeX Therapeutics, Inc.$11.10 NSRX

1.2055+18.92%

Nasus Pharma Ltd.$7.58 CYBN

0.41+6.06%

Cybin Inc.$7.18 ARMP

0.76+14.07%

Armata Pharmaceuticals, Inc.$6.16 NBY

2.35+79.66%

NovaBay Pharmaceuticals, Inc.$5.30 CVM

-0.59-10.73%

CEL-SCI Corporation$4.91 PHGE

0.25+13.30%

BiomX Inc.$2.13 PLX

-0.065-3.62%

Protalix BioTherapeutics, Inc.$1.73

Company Overview

Can-Fite BioPharma Ltd. (AMEX:CANF) closed at $0.24 USD, losing -$0.01 (-2.94%) from the previous close of $0.25. The stock is currently within 5% of its 52-week low $0.24 and $2.33. With a market capitalization of about $2.63 million, Can-Fite BioPharma Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.03). Key stats such as the average daily volume over the past year has been around 6.46 million shares, volume is running light vs its 52-week average. Headquartered in Petah Tikva, None, Can-Fite BioPharma Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Motti Farbstein, the company employs approximately 5 people and listed since November 06, 2012. Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction.

Technical Performance

CANF has shown weak momentum, losing -12.8% over the past week and -61.02% over the past quarter, though year-to-date performance is down -84.53%. Short-term trend indicators are bullishly aligned (SMA20 -19.34%, SMA50 -35.1%, SMA200 -70.47%). The stock’s 14-day RSI is 30.77 (weak momentum), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -89.18% below its high and over 2.69% above its low. Average 10-day trading volume of 846.01 thousand shares is below the 3-month average of 6.38 million, indicating normal recent market interest.

Valuation Metrics

Can-Fite BioPharma Ltd. trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 4.7 and a price-to-book ratio of 0.67 suggesting the stock is closer to book value. The P/FCF stands at -0.31, also below market averages.

Dividend & Fair Value

Can-Fite BioPharma Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.17. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Can-Fite BioPharma Ltd. generated EPS of $nan over the past year. Five-year average earnings growth is 52.31%. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.14. Next year's EPS is expected at $53.99. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 12 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $2.50. The high target offers 4300.0% upside. The low target suggests 900.0% downside. The mean target is $9.71. This offers 3784.0% upside. Can-Fite BioPharma Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 14, 2025, missed forecasts by -20.83%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in October 03, 2024.

Shareholding & Insider Activity

Can-Fite BioPharma Ltd. has 14.57 million shares outstanding. The public float is 3.75 billion shares, elevated short interest at 0.87% of float. This equals 127.42 thousand shares. The short ratio is 0.43 days. Institutional investors hold 5.89% of the float. Insiders own 0.0%.

Financial & Profitability Overview

Over the trailing twelve months, Can-Fite BioPharma generated $743.00K in revenue, or $0.17 per share. Gross margin was 97.98%, operating margin -1102.96%, and net profit margin -1027.46%. Returns are negative, with ROA at -76.42% and ROE at -122.28%.
On valuation metrics, Can-Fite BioPharma trades at a P/E of -0.32, P/S of 4.70 and P/B of 0.67. The current ratio is 3.60 and quick ratio is 3.60. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -92.81.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Can-Fite BioPharma posted revenue of $743.00K, down slightly from $810.00K in the prior quarter. Gross profit was $728.00K (margin 97.98%). Operating income was - $8.20M (margin -1103.0%). Net income was- $7.63M (EPS - $1.79).
The company ended the quarter with $8.92M in cash and short-term investments, a total debt of $40.00K, and net debt of - $4.24M. Total assets were $9.99M, with equity of $6.24M. Financials further reflected weakness, with operating cash flow of - $8.44M, free cash flow of - $8.44M, and capital expenditures of - $2.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Can-Fite BioPharma Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.7%, with price expected at $0.21 by January 02, 2026, within a range of $0.18 to $0.24 3-Month Outlook: Projected fall of -72.23%, reaching $0.07 by March 19, 2026, with a range of $0.02 to $0.12. 1-Year Outlook: Projected loss of -76.2%, with price at $0.06 by December 18, 2026, within a range of $0.00 to $0.00.

Key Takeaways

Can-Fite BioPharma Ltd. (AMEX:CANF) shares are down -84.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Can-Fite BioPharma Ltd. trading at a premium to the broader market with a P/E of -0.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $11.30, suggesting 4382.35% upside. Our AI forecast model points to short-term weakness (-16.7% over two weeks), a medium-term fall (-72.23% over three months), and a longer-term loss (-76.2% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Can-Fite BioPharma Ltd. (CANF) stock price?

Can-Fite BioPharma Ltd. (AMEX: CANF) stock price is $0.24 in the last trading session. During the trading session, CANF stock reached the peak price of $0.26 while $0.24 was the lowest point it dropped to. The percentage change in CANF stock occurred in the recent session was -2.94% while the dollar amount for the price change in CANF stock was - $0.01.

CANF's industry and sector of operation?

The AMEX listed CANF is part of Biotechnology industry that operates in the broader Healthcare sector. Can-Fite BioPharma Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CANF?

Dr. Vibeke Strand FACP, FACR, FACR (USA), M.D.
Senior Clinical Advisor
Dr. Sari Fishman Ph.D.
Vice President of Bus. Devel.
Dr. Pnina Fishman Ph.D.
Founder, Chief Scientific Officer & Executive Chairman
Dr. Vibeke S. Strand FACP, FACR, FACR (USA), M.D.
Senior Clinical Advisor
Mr. Motti Farbstein
Chief Executive Officer & Chief Operating and Financial Officer
Dr. Ilan Cohn Ph.D.
Co-Founder & Director

How CANF did perform over past 52-week?

CANF's closing price is 2.9% higher than its 52-week low of $0.24 where as its distance from 52-week high of $2.33 is -89.18%.

How many employees does CANF have?

Number of CANF employees currently stands at 5.

Link for CANF official website?

Official Website of CANF is: https://www.canfite.com

How do I contact CANF?

CANF could be contacted at phone 972 392 41114 and can also be accessed through its website. CANF operates from 10 Bareket Street, Petah Tikva, 4951778, Israel.

How many shares of CANF are traded daily?

CANF stock volume for the day was 977.59K shares. The average number of CANF shares traded daily for last 3 months was 6.46M.

What is the market cap of CANF currently?

The market value of CANF currently stands at $2.63M with its latest stock price at $0.24 and 10.76M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	0.03
Sales or Revenue	$743.00K
5Y Sales Change%	-0.994%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CANF Company Profile and Key Details

Can-Fite BioPharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics